Literature DB >> 3492346

Predictors of acute relapse of Crohn's disease. A laboratory and clinical study.

J P Wright, G O Young, N Tigler-Wybrandi.   

Abstract

Relapses of Crohn's disease appear to be almost random. If these attacks could be reliably predicted, it might be possible to abort them with early treatment. In order to identify laboratory and clinical parameters that would predict an acute relapse, patients who had been assessed clinically in the three months prior to an attack were studied. Published clinical indices as well as variety of laboratory parameters were measured. The clinical indices and the serum C-reactive protein, orosomucoid, alpha 1-antitrypsin, and iron were increased at the time of the attack as compared to three months earlier, while only the clinical indices, orosomucoid and alpha 1-antitrypsin increased between three months and one month prior to the attack. There was a poor correlation of the parameters to each other. Further prospective studies are needed to determine the specificity of the suggested indices in predicting acute relapses of Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3492346     DOI: 10.1007/BF01297104

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  A structural study of human exocrine IgA globulin.

Authors:  R W Newcomb; D Normansell; D R Stanworth
Journal:  J Immunol       Date:  1968-11       Impact factor: 5.422

2.  Fibinolysis in colonic disease.

Authors:  C H Swan; J A Williams; W T Cooke
Journal:  Gut       Date:  1970-07       Impact factor: 23.059

Review 3.  Gonadotropins and their subunits: basic and clinical studies.

Authors:  J L Vaitukaitis; G T Ross; G D Braunstein; P L Rayford
Journal:  Recent Prog Horm Res       Date:  1976

4.  Human chorionic gonadotropin and alpha chain of glycoprotein hormones in patients with inflammatory bowel disease.

Authors:  W Kruis; K Mann
Journal:  Eur J Clin Invest       Date:  1983-04       Impact factor: 4.686

5.  Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index.

Authors:  C Andre; L Descos; P Landais; J Fermanian
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

6.  Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis.

Authors:  E A Fagan; R F Dyck; P N Maton; H J Hodgson; V S Chadwick; A Petrie; M B Pepys
Journal:  Eur J Clin Invest       Date:  1982-08       Impact factor: 4.686

Review 7.  Recent developments in nonspecific inflammatory bowel disease (second of two parts).

Authors:  J B Kirsner; R G Shorter
Journal:  N Engl J Med       Date:  1982-04-08       Impact factor: 91.245

8.  Transcobalamin II level in peripheral blood monocytes--a biochemical marker in inflammatory diseases of the bowel.

Authors:  D Rachmilewitz; M Ligumsky; B Rachmilewitz; M Rachmilewitz; N Tarcic; M Schlesinger
Journal:  Gastroenterology       Date:  1980-01       Impact factor: 22.682

9.  Normal serum alkaline phosphatase isoenzymes examined by acrylamide and starch gel electrophoresis and by isoenzyme analysis using organ-specific inhibitors.

Authors:  S Green; F Cantor; N R Inglis; W H Fishmann
Journal:  Am J Clin Pathol       Date:  1972-01       Impact factor: 2.493

10.  Alpha 2-macroglobulin in patients with inflammatory bowel disease.

Authors:  D J Brown; J A Khan; G Copeland; D P Jewell
Journal:  J Clin Lab Immunol       Date:  1980-07
View more
  12 in total

Review 1.  Assessing disease activity and disease activity indices for inflammatory bowel disease.

Authors:  Feng Xiao Li; Lloyd R Sutherland
Journal:  Curr Gastroenterol Rep       Date:  2002-12

Review 2.  Current advantages in the application of proteomics in inflammatory bowel disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; George Theodoropoulos; George Zografos
Journal:  Dig Dis Sci       Date:  2012-06-28       Impact factor: 3.199

3.  Use of the Crohn's disease activity index in clinical trials of biological agents.

Authors:  Hugh-J Freeman
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

4.  Intestinal permeability in gastrointestinal disorders. Use of oral [99mTc]DTPA.

Authors:  R H Resnick; H Royal; W Marshall; R Barron; T Werth
Journal:  Dig Dis Sci       Date:  1990-02       Impact factor: 3.199

Review 5.  Non-invasive investigation of inflammatory bowel disease.

Authors:  J A Tibble; I Bjarnason
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

6.  Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy.

Authors:  James Turvill
Journal:  Frontline Gastroenterol       Date:  2014-04-16

7.  Overexpression of alpha(1)-acid glycoprotein in transgenic mice leads to sensitisation to acute colitis.

Authors:  T Hochepied; A Wullaert; F G Berger; H Baumann; P Brouckaert; L Steidler; C Libert
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 8.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

9.  Factors affecting plasma postheparin diamine oxidase activity.

Authors:  J S Thompson; D A Burnett; W P Vaughan
Journal:  Dig Dis Sci       Date:  1991-11       Impact factor: 3.199

10.  Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

Authors:  T Sahmoud; G Hoctin-Boes; R Modigliani; A Bitoun; J F Colombel; J C Soule; C Florent; J P Gendre; E Lerebours; R Sylvester
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.